Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW to Use Senshin-iryo System to Develop Anticancer Drugs from FY2013
July 30, 2012
- MHLW Approves Class 1 OTC Drugs for Allergic Rhinitis
July 30, 2012
- MHLW Reports Revisions of Package Insert for Telavic
July 27, 2012
- PAFSC’s 2nd Committee Recommends Approval of 2 DPT-IPV Vaccines; Introduction Expected in November
July 26, 2012
- PAFSC’s 2nd Committee Recommends Orphan Drug Designation for 3 Products Including Thyroid Cancer Treatment
July 26, 2012
- MHLW Asks Sanofi Pasteur to Consider Reducing Price of IPV
July 25, 2012
- MHLW Approves Revision to Kitasato Daiichi Sankyo Vaccine’s Management Resource Reuse Plan
July 25, 2012
- PAFSC’s First Committee to Review 4 Products Including Lotriga from Takeda on August 3
July 24, 2012
- PAFSC’s Second Committee Recommends Approval for Symbicort for COPD
July 24, 2012
- NIBIO to Play Important Role in Collaboration between Industry, Government, Academia: Director General Yamanishi
July 24, 2012
- Expert Panel Recommends Priority Measures Including Pediatric Drug Development for FY2013 Budget
July 23, 2012
- Mix of Differential Pricing and Generic Drug Use Promotion Policies Can Help Reduce Drug Expenditure: Prof. Sakamaki
July 23, 2012
- MHLW Study Group Launches Info Website on Epilepsy Treatment Facilities
July 23, 2012
- Vaccines Are Good Investments: Dr Warton of CDC
July 23, 2012
- Industry Representatives Express Concern over Large Reductions in Prices of Long-Listed Drugs at CSIMC
July 20, 2012
- Industry Figures Stress Positive Impact of Premium for Generic-Name Prescribing at CSIMC
July 20, 2012
- Cost-Effective Assessments to Be Limited to Technologies for Which Alternatives Are Available: CSIMC
July 19, 2012
- PAFSC’s 2nd Committee on Drugs to Review 2 Combination DPT-IPV Vaccines on July 20
July 19, 2012
- Establishment of Relief System for Victims of Health Damage Due to Anticancer Drugs Should Be Put Off: MHLW Study Group
July 17, 2012
- Draft Revitalization Strategy Calls for Screening of 100 Drug Seeds through Drug Discovery Support Network by FY2015
July 13, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…